Weekend update

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC,

  • Roll Call offers more details on this week’s Capitol Hill activities here.
  • The Wall Street Journal reports,
    • “The Pan American Health Organization has revoked the measles-elimination status of the U.S., according to people familiar with the matter.
    • “The U.S. CDC has reported more than 5,400 measles cases in 2026, a level not seen since before the disease was eliminated in 2000.
    • “To regain elimination status, the U.S. must halt the continuous spread of the highly infectious disease for at least 12 months.”
  • The Office of Management and Budget’s Office for Information and Regulatory Affairs has cleared for publication in the Federal Register that Department of Health and Human Services’s Office for Civil Rights long awaited “HIPAA Privacy Rule: Changes to Support Coordinated Care and Individual Engagement and Reduce Regulatory Burdens” final rule. The final rule should appear in the Federal Register this week.

From the U.S. Office of Personnel Management front

  • The Federal Employee Benefits Open Season heads into its second week tomorrow.
  • Serving Those Who Serve offers guidance on how to get all of the tax benefits from a health savings account.

From the judicial front,

  • In Human Rights Campaign’s case against OPM over its ban on gender affirming care in the FEHB and PSHB Programs, the federal district judge Hon. Amit P. Mehta issued the following briefing order last Thursday.”
    • “MINUTE ORDER setting the schedule for further proceedings in this matter: (1) Defendants shall file a consolidated Opposition to Plaintiffs’ Motions for Preliminary Injunction and Provisional Class Certification and Cross-Motion to Dismiss on or before November 24, 2026; (2) Plaintiffs shall file a consolidated Reply in Support of their Motions for Preliminary Injunction and Provisional Class Certification and Opposition to Defendants’ Cross-Motion to Dismiss on or before December 7, 2026; and (3) Defendants shall file their Reply in Support of their Cross-Motion to Dismiss on or before December 14, 2026. Signed by Judge Amit P. Mehta on 11/12/2026. (lcapm2) (Entered: 11/12/2026).”

From the public health and medical / Rx research front,

  • Health Exec reports,
    • “Note to patients suffering low-back pain without having signs or symptoms of severe injury or illness: You’ll do well for yourself—and for U.S. healthcare—to get an X-ray at an urgent-care clinic rather than going to a hospital emergency room for more advanced imaging. 
    • “That’s the conclusion of researchers who found only 24 of almost 3,000 urgent-care lumbar X-rays—less than 1%—preceded a pricey CT or MRI scan at an ER within 30 days. 
    • “The low follow-up rate adds to evidence suggesting most low-back pain subsides without need for additional imaging, much less professional intervention or other downstream episodes of care. 
    • “Given the population-level pattern, the findings suggest, a quick X-ray can help confidently rule out serious harm when none appears to be present. 
    • “This should come as good news to watchers of medical spending, as advanced imaging for low-back pain has often been referred to as the “poster child” for healthcare overutilization.” 
  • Healio relates,
    • “The cost of GLP-1 receptor agonists is one of the strongest predictors for continued medication use among adults with diabetes or obesity, according to a speaker at ObesityWeek.
    • “In an analysis of data from adults in the U.S. who participated in the Understanding America Study (UAS), researchers examined GLP-1 efficacy and usage in a real-world setting. Weight loss totals in the study were similar to what were observed in clinical trials, but the study found that 33.4% of participants stopped treatment. Additionally, discontinuation was more likely among those who were paying more than $51 per month in out-of-pocket spending.
    • “Cost, not just side effects, shapes who gets these drugs and who stays on them,” Alison Sexton Ward, PhD, senior scholar and research scientist at the University of Southern California Schaeffer Institute for Public Policy and Government Service, told Healio. “Need drives interest: People with higher BMI or [worse] diabetes are much more interested in GLP-1s than people with lower BMI. But income and insurance determine who actually starts. And once people start, paying more than $50 a month out of pocket raises the risk of stopping as much as, or more than, having vomiting as a side effect. These drugs can produce substantial weight loss that builds over time, but only for people who can afford to stay on them.”
  • and
    • “Adults with obesity who used either semaglutide or tirzepatide at baseline were able to maintain weight loss at 2 years across four separate treatment regimens, according to data presented at ObesityWeek.
    • “In an analysis of data from adults with obesity who were using either injectable once-weekly semaglutide (Ozempic/Wegovy, Novo Nordisk) or tirzepatide (Mounjaro/Zepbound, Eli Lilly) at baseline, researchers compared changes in body weight and other cardiometabolic parameters among different management strategies. While adults who underwent bariatric surgery achieved the largest weight loss at 2 years, those who switched between semaglutide and tirzepatide had a greater weight loss than those who remained on their baseline medication. All four groups who continued some form of obesity therapy had greater weight loss at 2 years than the group that stopped treatment.
    • “Our study highlights the importance of continued obesity management,” Hamlet Gasoyan, PhD, investigator at the center for value-based care research at Cleveland Clinic and assistant professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, told Healio. “These results could support patient-clinician discussions about alternative therapy options in patients who consider switching or stopping injectable semaglutide or tirzepatide.”
  • Health Day informs us,
    • “More than 1 in 5 U.S. adults report very high stress, and most now see it as unavoidable
    • “Chronic stress keeps the body in fight-or-flight mode, raising risks of heart disease, diabetes, depression and dementia
    • “Time outdoors, healthy eating, rest, less news and staying connected can help keep stress from turning chronic.
  • and
    • “Multiple trips to the ER. Treatment for a severe allergic reaction. And years without the right diagnosis.
    • “Two new studies reveal how a condition called eosinophilic esophagitis, or EoE, is being mistaken for severe food allergies.
    • “Researchers say diagnoses have increased sevenfold since 2009.
    • “EoE is a chronic condition often triggered by foods like dairy and wheat.
    • “Unlike a typical food allergy, it causes a buildup of white blood cells in the esophagus — the tube connecting your mouth to your stomach.
    • “This causes swelling and irritation. Over time, it can make swallowing difficult and cause food to get stuck. * * *
    • “Experts urged people with recurring swallowing problems but negative tests for food allergies to speak with their doctor.
    • “Early diagnosis and treatment can help prevent lasting damage to the esophagus.”

From the U.S. healthcare business front,

  • AlphaSense lists the 50 largest healthcare companies by market cap.
    • “Eli Lilly is the largest company in the healthcare and pharma space, with a market cap of $1.29 trillion.
    • “Eli Lilly is followed by Johnson & Johnson ($655.46 billion), AbbVie ($511.22 billion), Merck & Co ($363.24 billion), and UnitedHealth Group ($355.78 billion). 
    • “The largest market cap companies mostly fall into the pharma and health insurance sub-sectors.
    • “Biotech, medical devices, and medtech are some of the fastest growing sub-sectors.”
  • The American Medical Association points out,
    • “9 health systems finding success in physician recruitment, retention
      • “From mentorship to well-being, health systems across the U.S. are finding creative ways to improve work environments to keep doctors engaged.”
  • Per Business Wire,
    • “Unified Women’s Healthcare (Unified), one of the nation’s largest women’s healthcare organizations, is leading a new initiative to explore how routine OB/GYN care can play a greater role in identifying and addressing cardiovascular disease risk among women. Early support from the American Heart Association Go Red for Women Venture FundTM for a feasibility study by Unified’s Lucina Analytics subsidiary laid the groundwork for the initiative. Building on that foundation, Unified is leveraging Lucina’s AI-driven intelligence and embedded care management capabilities to help OB/GYN teams identify patients at elevated cardiovascular risk and connect them with care tailored to their risk level.
    • “Cardiovascular disease remains the leading cause of death among women in the United States, yet opportunities to identify risk factors and intervene early are often missed. For many women, their OB/GYN is their most consistent point of contact within the healthcare system, creating an important opportunity to integrate cardiovascular prevention into care they already receive.
    • “The Unified initiative seeks to bridge this gap by developing a scalable approach to cardiovascular risk assessment within women’s healthcare settings, with the long-term goal of helping clinicians identify women at elevated risk earlier and connect them with appropriate preventive services and specialty care.”

Leave a Reply

Your email address will not be published. Required fields are marked *